Τίτλος:
Pharmacotherapeutic strategies for castrate-resistant prostate cancer
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Introduction: Metastatic castration-resistant prostate cancer (CRPC) is a potentially symptomatic disease with an eventual lethal outcome. Novel pharmaceutical agents are continuously studied with encouraging results in CRPC. Areas covered: In this perspective, the authors present established and promising pharmacotherapeutic strategies for the management of CRPC; both with and without metastases. Apart from the different treatment strategies, the authors present the relevant sequence of treatment through disease progression. Expert opinion: Usually, docetaxel should be considered the first line treatment in mCRPC. Abiraterone acetate (AA) plus prednisone or enzalutamide (ENZ) could be alternative treatments in chemotherapy naïve patients. Sipuleucel-T has been approved for the treatment of asymptomatic or minimally symptomatic mCRPC. Ra-223 has been approved for patients with mCRPC with symptomatic bone metastases (not visceral metastases). Cabazitaxel has been approved as the second line treatment to docetaxel in mCRPC. No differences in the overall survival has been observed between sequences starting with docetaxel versus AA/ENZ. Between AA-to-ENZ and ENZ-to-AA sequence, the AA-to-ENZ sequence appeared to be more favorable than the ENZ-to-AA regarding progression-free survival but not overall survival. Carbazitaxel seemed to retain its activity regardless of the treatment sequence. Of note, ENZ and apalutamide have been approved in non-metastatic CRPC. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Moussa, M.
Papatsoris, A.
Abou Chakra, M.
Sryropoulou, D.
Dellis, A.
Περιοδικό:
Expert Opinion on Pharmacotherapy
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
abiraterone acetate; cabazitaxel; docetaxel; enzalutamide; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; prednisone; radium chloride ra 223; sipuleucel T; abiraterone; abiraterone acetate; androstane derivative; antineoplastic agent; cabazitaxel; docetaxel; enzalutamide; phenylthiohydantoin; prednisone; radium; Radium-223; sipuleucel T; taxoid; tissue extract, Article; asymptomatic disease; bone metastasis; cancer combination chemotherapy; cancer growth; cancer immunotherapy; cancer radiotherapy; cancer survival; castration; castration resistant prostate cancer; clinical effectiveness; enzyme inhibition; human; metastasis; overall survival; progression free survival; castration resistant prostate cancer; clinical trial (topic); disease free survival; drug effect; drug resistance; immunology; immunotherapy; male; metabolism; mortality; procedures, Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts
DOI:
10.1080/14656566.2020.1767069
